Loading...
Symbols:
Loading...
Symbols:
Dendreon (DNDN)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Dendreon (DNDN)
107 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on DNDN
- Mike Huckman(11)
- SA Editor Eli Hoffmann(8)
- Karuna Kanagaratnam(8)
- Alan Brochstein(8)
- SA Editor Miriam Metzinger(8)
Most popular authors
(tracked in watchlists)
- SA Editor Eli Hoffmann(379)
- Roger Nusbaum(311)
- Andrew Wilkinson(305)
- Stockerblog (158)
- SA Editor Joan Wickham(144)
Most commented on authors
- Theodore Cohen(64)
- Karuna Kanagaratnam(57)
- Maxim Jacobs(26)
- Mike Huckman(24)
- SA Editor Eli Hoffmann(22)
- Dendreon Gets Another Analyst Thumbs-Down
- A Biotech Bonanza for ImClone and Dendreon
- Stocks Potentially Impacted by SEC's Enforcement of Regulation SHO
- Are Dendreon's "Naked Shorts" Running For Cover?
- Five Presentations from the Recent Biotech Investment Conference
- Thursday Options Update: XLF, USO, DNDN, RDC, FL, CRM, SKS
- Updates on the Healthcare/Biotech Mergers
- Dendreon's Provenge: Government Agencies Play Hide and Seek With Facts
- Evaluating Cancer Drugs at the FDA
- Wall Street Breakfast: Must-Know News
- Dendreon: The Provenge Approval Scandal, One Year Later
- Five Biotech Stocks to Weather a Down Market
- Dendreon: The FDA's Commissioner Doth Protest Too Much!
- Dendreon's Secret "Lover" Revealed: It's Not Icahn
- Under The Radar News - Tuesday
- Antigenics, Dendreon and Cell Genesys Find Hope in Overseas Treatment Approvals
- Russian Roulette Pays Off for Antigenics
- World's First Cancer Vaccine Approved; Expect Interest in Antigenics, Dendreon
- Biotech Stocks: Sector Outlook and Top Picks
- Dendreon's Secret Investor
- Wall Street Breakfast: Must-Know News
- Dendreon's News - Good Spin, No Spunk
- A SPA Break for Dendreon
- FDA Turns Over Dendreon Documents - Here They Are
- How Genentech Got Its Groove Back
- The Current Status of Cancer Vaccines: An Overview
- Wall Street Breakfast: Must-Know News
- House Committee's Irrational Decision on Dendreon's Provenge COIs
- Dendreon Clinical Studies Continue to Impress
- Under The Radar News - Tuesday
- Good News for Dendreon, Bad News for Prostate Cancer
- Under The Radar News - Monday
- Dendreon Suffers from Immature Management
- A Low-Risk Dendreon Options Play
- Dendreon Soars on Alleged FDA Foul-Play
- Nine Stem Cell Stocks to Add to Your Portfolio
- Dendreon Has Competition: Northwest BioTherapeutics Gains Cancer Vaccine Approval
- Cancer Stocks: Tracking the Market
- Dendreon: Media Spotlight Generates Hype and Hysteria
- Dendreon Jumps on New Cancer Vaccine Report
- Cancer Stocks: The Bleeding Slows
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »